JP2024541905A5 - - Google Patents

Info

Publication number
JP2024541905A5
JP2024541905A5 JP2024524468A JP2024524468A JP2024541905A5 JP 2024541905 A5 JP2024541905 A5 JP 2024541905A5 JP 2024524468 A JP2024524468 A JP 2024524468A JP 2024524468 A JP2024524468 A JP 2024524468A JP 2024541905 A5 JP2024541905 A5 JP 2024541905A5
Authority
JP
Japan
Prior art keywords
fragment
immunoglobulin
artificially
amino acid
manipulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541905A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060324 external-priority patent/WO2023073599A1/en
Publication of JP2024541905A publication Critical patent/JP2024541905A/ja
Publication of JP2024541905A5 publication Critical patent/JP2024541905A5/ja
Pending legal-status Critical Current

Links

JP2024524468A 2021-10-28 2022-10-27 人工操作Fcバリアント Pending JP2024541905A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272955P 2021-10-28 2021-10-28
US63/272,955 2021-10-28
PCT/IB2022/060324 WO2023073599A1 (en) 2021-10-28 2022-10-27 Engineered fc variants

Publications (2)

Publication Number Publication Date
JP2024541905A JP2024541905A (ja) 2024-11-13
JP2024541905A5 true JP2024541905A5 (https=) 2025-10-15

Family

ID=84366307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524468A Pending JP2024541905A (ja) 2021-10-28 2022-10-27 人工操作Fcバリアント

Country Status (5)

Country Link
US (1) US20250011428A1 (https=)
EP (1) EP4423123A1 (https=)
JP (1) JP2024541905A (https=)
CN (1) CN118119642A (https=)
WO (1) WO2023073599A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250065477A (ko) * 2023-11-03 2025-05-13 고려대학교 산학협력단 작용기 기능이 제거된 Fab-arm 교환 방지 Fc 변이체들
WO2026014615A1 (ko) * 2024-07-10 2026-01-15 고려대학교 산학협력단 작용기 기능이 제거된 신규 당화 fc 변이체
CN120718139B (zh) * 2025-08-14 2025-11-11 成都蓉生药业有限责任公司 一种免疫球蛋白Fc变体、基因、表达载体、宿主细胞、多肽、抗体、融合蛋白药物及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2004266159A1 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT2099823E (pt) * 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Fc 리간드 친화성이 감소된 항-IFNAR1 항체
EP2711018A1 (en) * 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
US10526408B2 (en) * 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
MX2021010254A (es) * 2019-02-27 2021-09-21 Angiex Inc Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
AU2022218544B2 (en) Hetero-dimeric multi-specific antibody format
JP2024541905A5 (https=)
JP7138046B2 (ja) 二特異性抗体基幹
CN109641949B (zh) 促进选择性轻链配对的多特异性抗体
JP2019519528A (ja) 操作されたFcコンストラクトに関する組成物及び方法
US20220363782A1 (en) Orthogonal mutations for heterodimerization
JP2024502095A (ja) 二重または多重特異性抗体{Bi or Multi-Specific Antibody}
EP4438614A1 (en) Methods for purifying heteromultimeric antibodies
WO2025092987A1 (zh) 基于Fc区的异二聚体分子及其用途
JP2026510494A (ja) ヒトCD1b(分化抗原群1)タンパク質のヘテロ二量体を含む抗体様分子
HK40079873A (en) Hetero-dimeric multi-specific antibody format
EA041608B1 (ru) Гетеродимерный полиспецифичный формат антител